Detected NRAS mutations occurred exclusively at the known hotspot residues p.G12, p.G13, and p.Q61 representing gain of function mutations in various cancer entities including multiple myeloma (MM)25–27. This evidence concerns the gene NRAS and plasma cell myeloma.